Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 22, Pages 9914-9928Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm301113w
Keywords
-
Categories
Funding
- Medicen Paris Region Competitiveness Cluster [I06-222/R, I09-1739/R]
- Seine-Saint-Denis County
Ask authors/readers for more resources
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from. its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically, relevant Gram negative bacteria that is currently undergoing clinical trails.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available